Zepbound review: is it worth it?
Zepbound (tirzepatide) is a dual GIP/GLP-1 agonist FDA-approved for chronic weight management and OSA with obesity.
Status update: No formal taper required. Expect weight regain similar to other GLP-1s (~2/3 of loss over 12 months){cite:1}. Many patients continue indefinitely as chronic therapy. Pair stopping with intensive behavioral support if available.
On this page
The most effective FDA-approved weight-loss drug to date
The most effective FDA-approved weight-loss drug to date
If you qualify on BMI and can secure coverage or self-pay pricing, Zepbound has delivered the largest average weight loss of any approved obesity medication in head-to-head data, and it is the only GLP-1-based drug also cleared for moderate-to-severe sleep apnea. The trade-offs are real: it is an indefinite weekly injection, often causes nausea, and can cost hundreds to over a thousand dollars a month depending on your coverage. For many eligible adults who have struggled with diet and exercise alone, the efficacy is hard to beat, but only a licensed clinician can decide whether it is appropriate for you.
- May be covered by insurance
We may earn a commission if you buy through this link, at no extra cost to you. It never affects our score. How we make money
- Personal or family history of medullary thyroid carcinoma (MTC): Zepbound is absolutely contraindicated. In rodents, tirzepatide causes dose- and duration-dependent thyroid C-cell tumors; human relevance is unknown, so patients with a personal or family history of MTC must not use it. Counsel on symptoms of thyroid tumors (neck mass, dysphagia, dyspnea, persistent hoarseness). (FDA label, Section 4 / Boxed Warning)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2): absolutely contraindicated, due to the associated risk of medullary thyroid carcinoma. (FDA label, Section 4 / Boxed Warning)
- Known serious hypersensitivity to tirzepatide or any excipient in Zepbound: contraindicated. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported. (FDA label, Section 4)
- Not a Section 4 contraindication but a labeled precaution: pregnancy. Tirzepatide may cause fetal harm; weight management with Zepbound is not recommended during pregnancy, and it should generally be discontinued when pregnancy is recognized. Also use with caution in a history of pancreatitis, severe gastrointestinal disease (e.g., gastroparesis), or diabetic retinopathy, as these were not adequately studied / may worsen. (FDA label, Sections 5 and 8)
- Most effective FDA-approved weight-loss medication to date, with up to about 22.5% average body-weight loss at the 15 mg dose in SURMOUNT-1
- Demonstrated head-to-head superiority over Wegovy (20.2% vs 13.7%) in the SURMOUNT-5 NEJM trial
- Convenient once-weekly injection with a flexible dosing window (can be taken up to 4 days late)
- Dual GIP/GLP-1 mechanism, plus a second FDA indication for moderate-to-severe obstructive sleep apnea in adults with obesity
- More affordable paths than the list price: Lilly self-pay vials ($299-$449/month), a $25 commercial savings card, and new Medicare coverage for obesity rolling out in 2026
- Common gastrointestinal side effects (nausea, diarrhea, vomiting, constipation), especially during dose increases, which lead some people to stop treatment
- Expensive without good coverage; the list price is over $1,000/month and self-pay can run hundreds per month indefinitely, and coverage still varies by plan
- Effects are not permanent: weight regain is common after stopping, making it a likely long-term commitment
- Carries an FDA boxed warning for thyroid C-cell tumors and is contraindicated in people with a personal or family history of medullary thyroid cancer or MEN 2
- Prescription-only with required dose titration, plus rare but serious risks like pancreatitis, gallbladder disease, and acute kidney injury
In-depth review
What is Zepbound and what is it FDA-approved for?
Zepbound is the brand name Eli Lilly uses for tirzepatide when it is prescribed for weight and sleep apnea. The identical molecule is sold as Mounjaro for type 2 diabetes — same drug, same pens, different label and indication. The FDA first approved Zepbound on November 8, 2023 as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults who are either obese (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol (FDA).
On December 20, 2024, the FDA approved a second indication: moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. This made Zepbound the first prescription drug ever approved specifically to treat OSA, rather than just the CPAP machines and surgical options that previously dominated treatment (FDA; Eli Lilly).
What Zepbound is *not*: it is not a quick fix, not a cosmetic-only product, and not approved for people with a normal BMI who simply want to lose a few pounds. It is a chronic-disease medication intended for ongoing use, and the trials supporting it were all conducted alongside diet and exercise counseling.
How does tirzepatide actually work?
Most GLP-1 weight-loss drugs (semaglutide/Wegovy, liraglutide/Saxenda) act on a single hormone receptor. Tirzepatide is a dual agonist — a single molecule that activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. Both GIP and GLP-1 are "incretin" hormones your gut releases after eating.
Activating these receptors produces several effects that together drive weight loss:
- Slowed gastric emptying, so food stays in the stomach longer and you feel full sooner and for longer.
- Reduced appetite and food cravings, mediated largely through receptors in the brain's appetite centers.
- Improved insulin secretion and glucose control, which is why the same molecule is also a diabetes drug.
The dual GIP/GLP-1 mechanism is the leading hypothesis for *why* tirzepatide tends to outperform single-agonist GLP-1 drugs, though researchers still don't fully understand the relative contribution of GIP. It is given as a once-weekly subcutaneous injection into the abdomen, thigh, or upper arm, on any day of the week with or without food.
How well does Zepbound work? (the trial numbers)
The headline data come from SURMOUNT-1, a 72-week, placebo-controlled trial of 2,539 adults with obesity (or overweight plus a complication) *without* diabetes. Participants received 5 mg, 10 mg, or 15 mg of tirzepatide, or placebo, alongside lifestyle counseling (NEJM 2022; PMID 35658024). Average weight loss:
- 5 mg: about 15% of body weight (roughly 34 lb on average)
- 10 mg: about 19.5%
- 15 mg: about 20.9% (roughly 48 lb on average)
- Placebo: about 3% (roughly 7 lb)
For context, losing 15–21% of body weight with a drug is closer to what was historically seen only with bariatric surgery than with previous-generation weight-loss medications. A large share of participants on the higher doses lost at least a quarter of their starting body weight.
In people with type 2 diabetes (SURMOUNT-2, published in *The Lancet* 2023), weight loss was somewhat lower — a mean of 13.4% at 10 mg and 15.7% at 15 mg versus 3.3% on placebo over 72 weeks (Lancet 2023). Weight loss is consistently more modest in diabetics across this entire drug class, so this is expected, not a red flag.
How does it compare directly to Wegovy?
This is the question most people actually want answered, and unusually we have a *direct* head-to-head trial. SURMOUNT-5 (published in the *New England Journal of Medicine*, May 2025; PMID 40353578) randomized adults with obesity but without diabetes to maximum-tolerated tirzepatide or maximum-tolerated semaglutide (Wegovy) for 72 weeks. At week 72:
- Tirzepatide: about 20.2% mean body-weight reduction
- Semaglutide: about 13.7% mean body-weight reduction
Tirzepatide also produced a significantly greater reduction in waist circumference (−18.4 cm vs −13.0 cm, p<0.001), and overall treatment-discontinuation rates due to adverse events were low and broadly similar between the two drugs, with gastrointestinal events the most common in both groups (NEJM 2025; PMID 40353578). This is the strongest evidence to date that Zepbound is, on average, the more effective of the two leading obesity drugs — though "on average" is doing real work here, since individual responses vary widely and some people tolerate semaglutide better.
For sleep apnea
In the SURMOUNT-OSA trials, tirzepatide reduced the apnea-hypopnea index (AHI, a measure of breathing interruptions per hour) by about 25–29 events per hour versus roughly 5 with placebo, and a meaningful share of participants reached the threshold for OSA remission (NEJM 2024; PMID 38912654; FDA). This is the basis for the second FDA approval.
How is Zepbound dosed and titrated?
Zepbound is deliberately started low and increased slowly to limit nausea and GI side effects. The FDA-approved schedule is:
- Start: 2.5 mg once weekly for 4 weeks (this is a *starting* dose, not a maintenance dose — it's not expected to produce much weight loss).
- Then: increase to 5 mg weekly.
- After that: increase in 2.5 mg steps no sooner than every 4 weeks as tolerated.
Available strengths are 2.5, 5, 7.5, 10, 12.5, and 15 mg, in either single-dose prefilled pens or single-dose vials. The recommended maintenance doses are 5 mg, 10 mg, or 15 mg; 7.5 and 12.5 mg are primarily intermediate steps for people who need a slower climb. The maximum dose is 15 mg/week.
The slow titration matters: most people who quit do so during dose escalation because of nausea, so there is no medical benefit to rushing. If side effects are intense at a given dose, guidelines support staying longer at the current step before moving up.
What are the side effects, warnings, and contraindications?
Common side effects are overwhelmingly gastrointestinal and tend to peak shortly after each dose increase, then fade as the body adapts. Across trials these included nausea (~25–30%), diarrhea (~20%), constipation (~10%), and vomiting (~10%), along with abdominal pain, indigestion, and injection-site reactions (FDA label).
Serious but less common risks include:
- Pancreatitis (inflammation of the pancreas) — uncommon but requires stopping the drug and seeking care for severe, persistent abdominal pain.
- Gallbladder problems, including gallstones and cholecystitis — somewhat more likely with rapid weight loss.
- Acute kidney injury, usually driven by dehydration from severe vomiting or diarrhea.
- Hypoglycemia (low blood sugar), mainly when combined with insulin or sulfonylureas.
- Severe GI reactions and reports of ileus (impaired bowel movement).
Boxed warning: In rodent studies tirzepatide caused thyroid C-cell tumors. It is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) (FDA boxed warning).
Other important cautions:
- Because Zepbound slows stomach emptying, it can reduce the absorption of oral medications, including oral contraceptives — Lilly advises that women on the pill consider a non-oral birth control method or add a barrier method for 4 weeks after starting and after each dose increase.
- It should not be used in pregnancy (weight loss is not recommended during pregnancy) and there is a registry for those who become pregnant while on it.
- It has not been studied in combination with other GLP-1 drugs.
- People with a history of pancreatitis, diabetic retinopathy, or gastroparesis need individualized assessment.
A practical, under-discussed downside: muscle loss. Rapid weight loss of any kind includes lean mass, so adequate protein intake and resistance exercise during treatment are widely recommended by clinicians, even though the label doesn't mandate them.
Who is Zepbound best for — and who should skip it?
Good candidates generally include adults who meet the BMI criteria (≥30, or ≥27 with a weight-related condition), have tried lifestyle changes without durable success, and are prepared for long-term, possibly indefinite treatment. Studies show that when people stop the drug, much of the lost weight tends to return — so this is a maintenance medication, not a short course. People with moderate-to-severe OSA plus obesity now have a specific indication as well.
Who should be cautious or avoid it: anyone with the thyroid-cancer contraindications above; people with a history of pancreatitis or significant gallbladder disease; those who can't realistically afford ongoing cost; people seeking minor cosmetic weight loss; and anyone unwilling to pair it with dietary change, since the trials always included lifestyle support.
What does Zepbound cost and how do you get it?
This is where the honesty matters. Zepbound's list price is roughly $1,086 per month before any discounts (Eli Lilly). What you actually pay depends heavily on insurance:
- With commercial insurance that covers it: copays can be modest, and Lilly's savings card can lower out-of-pocket costs further for eligible patients. But many plans — and notably Medicare — do not cover GLP-1 drugs for weight loss alone, which leaves a large group paying cash.
- Self-pay via LillyDirect: Lilly sells single-dose vials (not the autoinjector pens) directly to cash patients. After a December 2025 price cut, these run roughly $299–$449/month depending on dose (2.5 mg around $299, 5 mg around $399, higher doses around $449), provided refills are kept within the program's timing window (Eli Lilly; CNBC, Dec 2025). Lower-tier refill pricing has timing conditions, so the effective price can rise if you fall outside the refill window. As of late 2025, vials are also available for pickup at thousands of Walmart pharmacies.
One critical access note: tirzepatide spent much of 2023–2024 on the FDA shortage list, which legally enabled compounding pharmacies to sell cheaper copies. That shortage is officially resolved, and the FDA ended enforcement discretion for compounded tirzepatide in early 2025 (503A pharmacies in February, 503B facilities in March). Mass-compounded tirzepatide is no longer permitted except in narrow, documented clinical cases — and cost savings alone does not qualify (FDA). Be skeptical of any vendor still selling cheap "compounded tirzepatide" as a routine alternative; it now operates in a legally and clinically gray zone.
How does Zepbound compare to the alternatives?
- vs. Wegovy/Ozempic (semaglutide): Zepbound produced greater average weight loss in the head-to-head SURMOUNT-5 trial (~20% vs ~14%), with comparable, mostly gastrointestinal tolerability in both arms. Semaglutide, however, has more long-term cardiovascular outcome data — the SELECT trial (NEJM 2023) showed semaglutide 2.4 mg cut major adverse cardiovascular events by about 20% in people with established heart disease and obesity but without diabetes — which can matter for patients with established heart disease. Tirzepatide's cardiovascular outcome trial is still maturing.
- vs. older drugs (phentermine, Contrave, Qsymia, Saxenda): these produce substantially less weight loss (typically single-digit to low-double-digit percentages) and are now second-line for most patients who can access an incretin drug.
- vs. bariatric surgery: surgery still generally produces the largest and most durable weight loss and remains the benchmark for severe obesity, but it is invasive and irreversible; Zepbound offers a meaningful, non-surgical option that approaches surgical results for some people while it's being taken.
The bottom line
Zepbound is, by the current evidence, the most effective FDA-approved weight-loss medication on the market — it beat Wegovy in a direct trial, delivers ~15–21% average weight loss depending on dose, and now treats obesity-related sleep apnea too. Those are genuinely strong, well-documented results from large randomized trials published in top journals.
The honest caveats are equally real: it's an injectable you likely take indefinitely, the GI side effects are common (if usually manageable), there is a boxed thyroid warning and several serious-but-rare risks, weight tends to return if you stop, and even after Lilly's price cuts the cost is a major barrier for anyone without coverage. It is a powerful, legitimate medical tool — best used under a clinician's supervision, alongside diet, protein-conscious eating, and resistance exercise, by people who fit the BMI criteria and can sustain it long term. For minor or cosmetic weight goals, or for anyone with the thyroid contraindications, it is the wrong choice.
How it works
Zepbound's active drug, tirzepatide, is a once-weekly injection that activates two gut-hormone receptors at once: GLP-1 and GIP. This "dual agonist" design is what sets it apart from GLP-1-only drugs like Wegovy. By mimicking these hormones, it curbs appetite, increases fullness, and slows how fast the stomach empties, so most people eat less and feel satisfied longer. It also improves how the body releases insulin and handles blood sugar. The result is sustained calorie reduction without the constant hunger that derails many diets.
Active ingredient: Tirzepatide
Effectiveness
In the pivotal 72-week SURMOUNT-1 trial (2,539 adults with obesity or overweight, without type 2 diabetes; published in the New England Journal of Medicine in 2022), tirzepatide produced average body-weight reductions of about 16.0% at 5 mg, 21.4% at 10 mg, and 22.5% at 15 mg, versus roughly 2.4% with placebo. In the head-to-head SURMOUNT-5 trial (751 participants, 72 weeks, NEJM 2025), Zepbound beat Wegovy (semaglutide) with an average 20.2% weight loss versus 13.7%, a 47% greater relative reduction; about 31.6% of Zepbound users lost at least 25% of their body weight versus 16.1% on Wegovy. Zepbound is also FDA-approved (December 2024) for moderate-to-severe obstructive sleep apnea in adults with obesity, where the SURMOUNT-OSA program showed clinically meaningful reductions in the apnea-hypopnea index versus placebo. Individual results vary with dose, diet, and activity.
What to expect over time
A realistic timeline of what Zepbound users typically experience. Individual results vary; this is educational, not medical advice.
- Weeks 1-4 (starting dose)
You begin at 2.5 mg injected once weekly. This is an initiation dose meant to let your body adjust, not a maintenance dose. GI side effects like nausea are the most common and typically start 1-3 days after the first shot, peaking around days 2-5 before easing within a week or two. Meaningful weight change is usually minimal this early.
- Weeks 5-20 (titration)
Your prescriber steps the dose up in 2.5 mg increments (5, 7.5, 10, 12.5, up to a 15 mg max) no sooner than every 4 weeks. Each increase can briefly bring back nausea or other GI symptoms that tend to settle as you stay on a dose. Appetite reduction and gradual, steady weight loss are commonly noticed during this phase; the 15 mg max is generally not reached before about week 20.
- Around week 12 (early-response check)
Clinicians often review progress around this point. In the SURMOUNT-1 trial, a slow start was not necessarily predictive of failure: a post hoc analysis found most people who had lost under 5% by week 12 still reached a clinically meaningful (5% or more) loss by week 72, especially on higher doses. By now most people have adapted and side effects have usually calmed.
- Months 4-12 (approaching full effect)
On a steady maintenance dose (5, 10, or 15 mg weekly), weight loss continues but typically slows toward a plateau. In SURMOUNT-1 the trial ran 72 weeks (about 16-17 months), with average reductions of roughly 16% on 5 mg, 21% on 10 mg, and 22.5% on 15 mg versus about 2.4% on placebo. Individual results vary widely; these are trial averages, not guarantees.
- Ongoing / long-term
Zepbound is intended as a long-term treatment alongside reduced-calorie diet and increased activity. Weight tends to plateau once you reach your effective maintenance dose, and trial and real-world data show much of the lost weight is commonly regained if the medication is stopped. Continued prescriber follow-up is needed to monitor dose, side effects, and overall health.
Side effects
The most common side effects are gastrointestinal and tend to appear during dose increases: nausea (reported in roughly 25-30% of users across the pivotal trials, and as high as the mid-30s in some studies), diarrhea, vomiting, constipation, abdominal pain, indigestion, and fatigue or injection-site reactions. These are usually mild-to-moderate and ease over time with slow titration, though they lead a small percentage of people to stop treatment. Less common but serious risks include pancreatitis (severe persistent abdominal pain), gallbladder problems including gallstones, acute kidney injury (often from dehydration due to vomiting or diarrhea), severe allergic reactions, and low blood sugar when combined with insulin or sulfonylureas. Zepbound carries an FDA boxed warning for thyroid C-cell tumors seen in rodent studies; whether it causes them in humans is unknown, but it is contraindicated in people with a personal or family history of medullary thyroid cancer or MEN 2. Seek care promptly for severe stomach pain, signs of an allergic reaction, or vision changes.
Safety: who should avoid it & interactions
- ✕Personal or family history of medullary thyroid carcinoma (MTC): Zepbound is absolutely contraindicated. In rodents, tirzepatide causes dose- and duration-dependent thyroid C-cell tumors; human relevance is unknown, so patients with a personal or family history of MTC must not use it. Counsel on symptoms of thyroid tumors (neck mass, dysphagia, dyspnea, persistent hoarseness). (FDA label, Section 4 / Boxed Warning)
- ✕Multiple Endocrine Neoplasia syndrome type 2 (MEN 2): absolutely contraindicated, due to the associated risk of medullary thyroid carcinoma. (FDA label, Section 4 / Boxed Warning)
- ✕Known serious hypersensitivity to tirzepatide or any excipient in Zepbound: contraindicated. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported. (FDA label, Section 4)
- ✕Not a Section 4 contraindication but a labeled precaution: pregnancy. Tirzepatide may cause fetal harm; weight management with Zepbound is not recommended during pregnancy, and it should generally be discontinued when pregnancy is recognized. Also use with caution in a history of pancreatitis, severe gastrointestinal disease (e.g., gastroparesis), or diabetic retinopathy, as these were not adequately studied / may worsen. (FDA label, Sections 5 and 8)
- MajorInsulin and insulin secretagogues (e.g., sulfonylureas such as glipizide, glyburide, glimepiride): Additive blood-glucose lowering raises the risk of hypoglycemia. In trials, hypoglycemia occurred in ~10.3% of patients on Zepbound plus a sulfonylurea vs ~2.1% on Zepbound without one. When starting Zepbound, the prescriber should consider reducing the dose of concomitant insulin or insulin secretagogue and monitor blood glucose. (FDA label (DailyMed), Section 7.1 / Section 6)
- MajorOral hormonal contraceptives (ethinyl estradiol/progestin pills): Zepbound delays gastric emptying and can reduce absorption of oral contraceptives, lowering their effectiveness and risking unintended pregnancy. Advise switching to a non-oral contraceptive method, or adding a barrier method, for 4 weeks after initiation and for 4 weeks after each dose escalation. (FDA label (DailyMed), Section 7.2 / Section 8)
- ModerateOral medications generally, especially narrow-therapeutic-index drugs (e.g., warfarin): By delaying gastric emptying, Zepbound can alter the rate/extent of absorption of concomitantly administered oral drugs. Use caution and monitor patients on medications with a narrow therapeutic index or that depend on threshold concentrations (e.g., monitor INR with warfarin). (FDA label (DailyMed), Section 7.2)
Sourced from FDA labeling and clinical references; not exhaustive and not a substitute for your prescriber or pharmacist. Always disclose every medication and supplement you take.
Cost
Starts at $299/mo from Eli Lilly.
As of September 2026, LillyDirect's regular self-pay price for a one-month Zepbound KwikPen supply is $299 for 2.5 mg, $399 for 5 mg, $499 for 7.5 mg and $699 for 10 mg, 12.5 mg or 15 mg; Lilly's Zepbound Journey Program can lower the higher-dose prices if you refill on schedule. Self-pay pricing can't be combined with insurance. With commercial insurance that covers Zepbound, Lilly's savings card can reduce the copay for eligible patients (monthly and annual caps apply). Coverage for weight loss varies by plan, so confirm your own benefits before starting, and budget for an ongoing monthly cost — it is a long-term medication.
LillyDirect self-pay (checked Sept 15, 2026), one-month KwikPen supply: $299 (2.5 mg), $399 (5 mg), $499 (7.5 mg), $699 (10, 12.5 or 15 mg).
Prices current as of May 29, 2026 and exclude promo codes; cash-pay and channel pricing change frequently — confirm with the pharmacy or provider.
Is it worth it?
Zepbound is the strongest weight-loss medication the FDA has approved to date, with demonstrated superiority over Wegovy in a head-to-head trial and a second indication for obstructive sleep apnea. It works only while you keep taking it, GI side effects are common early on, and affordability depends heavily on insurance, new government-coverage changes, or Lilly's self-pay vials. Discuss eligibility and the thyroid-tumor boxed warning with a clinician before starting. This is general information, not medical advice.
Frequently asked questions
How much weight can you lose on Zepbound?
In the 72-week SURMOUNT-1 trial, adults lost an average of about 16% of body weight at the 5 mg dose, 21.4% at 10 mg, and 22.5% at 15 mg, compared with roughly 2.4% on placebo. Individual results vary and depend on dose, diet, and activity. This is general information, not medical advice.
Is Zepbound better than Wegovy?
In the head-to-head SURMOUNT-5 trial, Zepbound produced greater average weight loss than Wegovy (20.2% vs 13.7% over 72 weeks), a 47% greater relative reduction. Zepbound's dual GIP/GLP-1 action appears more effective on average, but the right choice depends on your insurance coverage, tolerance, and your clinician's advice.
How much does Zepbound cost without insurance in 2026?
The list price is about $1,086 per month, but Lilly's self-pay vials cost roughly $299-$449 per month depending on dose. With commercial insurance coverage, the savings card can lower your copay to as little as $25 per month, and under a 2025 government agreement Medicare is set to cover Zepbound for obesity at about $50/month for eligible beneficiaries, rolling out in 2026. Confirm current pricing and your own coverage before starting.
What are the most common side effects of Zepbound?
Gastrointestinal effects are most common: nausea (roughly 25-30% of users in the pivotal trials), diarrhea, vomiting, and constipation, usually mild-to-moderate and worst during dose increases. Serious but rarer risks include pancreatitis, gallbladder problems, and kidney injury from dehydration. Tell your doctor about severe or persistent symptoms.
How is Zepbound dosed and injected?
It is a once-weekly injection under the skin (stomach, thigh, or upper arm). You start at 2.5 mg for 4 weeks, then increase by 2.5 mg no sooner than every 4 weeks as tolerated, up to a maximum of 15 mg weekly. Maintenance doses are 5, 10, or 15 mg. Follow your prescriber's specific instructions.
Who should not take Zepbound?
Avoid Zepbound if you or a family member has had medullary thyroid cancer (MTC) or MEN 2 syndrome, or if you have had a serious allergic reaction to tirzepatide. It is not recommended during pregnancy and is not approved for children. Use caution with a history of pancreatitis, gallbladder, or kidney disease, and discuss your full medical history with your doctor.
Will I regain the weight if I stop Zepbound?
Most people regain a significant portion of lost weight after stopping, because the appetite-suppressing effect ends when the medication does. Zepbound is generally intended as a long-term therapy, similar to medications for blood pressure or cholesterol. Do not stop on your own; discuss any changes with your doctor first.
Is Zepbound the same as Mounjaro?
Both contain the same active drug, tirzepatide, made by Eli Lilly. Zepbound is FDA-approved for chronic weight management and obstructive sleep apnea, while Mounjaro is approved for type 2 diabetes. They are branded for different uses but share the same molecule.
Does Zepbound treat sleep apnea?
Yes. In December 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity, the first medication cleared for this use. In the SURMOUNT-OSA program it significantly reduced apnea-hypopnea events versus placebo, and it may be used with or instead of CPAP depending on your doctor's guidance.
Sources
- ZEPBOUND (tirzepatide) injection — Full Prescribing Information — DailyMed, U.S. National Library of Medicine (2024)
- FDA Approves New Medication for Chronic Weight Management — U.S. Food and Drug Administration (2023)
- Tirzepatide injection: MedlinePlus Drug Information — MedlinePlus, U.S. National Library of Medicine (2024)
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — New England Journal of Medicine (2022)
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial — The Lancet (2023)
- Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial — Nature Medicine (2023)
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA) — New England Journal of Medicine (2024)
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) — New England Journal of Medicine (2025)
- Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1 3-year results) — New England Journal of Medicine (2024)
- Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight (SURMOUNT-1) — NCT04184622 — ClinicalTrials.gov, U.S. National Library of Medicine (2022)
- Insights into the Mechanism of Action of Tirzepatide: A Narrative Review — Diabetes Therapy (2025)
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist — JCI Insight (2020)
- Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials — Frontiers in Endocrinology (PMC) (2024)
- 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes—2026 — Diabetes Care, American Diabetes Association (2026)
- Tirzepatide — StatPearls — StatPearls, NCBI Bookshelf (2024)
- FDA Approves Lilly's Zepbound (tirzepatide) for Chronic Weight Management — Eli Lilly and Company (2023)
Ready to try Zepbound?
Check eligibility & price — from $299/mo- May be covered by insurance
Affiliate link — we may earn a commission at no extra cost to you, and it never changes our rankings or score. Disclosure
Related guides
Ways to save on Zepbound
Legitimate ways to lower your cost. We don’t sell Zepbound — this is independent guidance, not medical or financial advice. Confirm current terms with the program and your clinician.
- Manufacturer savings program
The maker of Zepbound runs a commercial-insurance savings program that can lower your copay. See the official Zepbound savings page → Eligibility rules apply and these programs typically exclude government insurance (Medicare/Medicaid).
- Patient assistance programs (PAPs)
If you’re uninsured or low-income, free or reduced-cost medication may be available through patient assistance programs. Search MedicineAssistanceTool (PhRMA) and NeedyMeds.
- Ask about a 90-day supply
Filling a 90-day supply instead of monthly often lowers the per-month cost and cuts pharmacy trips. Ask your prescriber and pharmacy whether it’s an option for you.
- Compare lower-cost alternatives
A different formulation or product may cost less for a similar result. Compounded GLP-1 · Supplements vs GLP-1.
How Zepbound compares
Same-category options, scored on the same six-axis rubric. Higher is better.